Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

NCT05604560 is registered in ClinicalTrials.gov with Lei Zheng as lead sponsor.

NCT NCT05604560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05604560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Lead sponsor
Lei Zheng
Phase
Phase 2
Overall status
Recruiting
Start date
November 8, 2023
Completion date
December 31, 2028
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer